4basebio AG / Key word(s): Corporate Action
20-Apr-2020 / 19:19 CET/CEST
4basebio AG resolves on capital reduction by way of redemption of approx. 5.2 million treasury shares in accordance with the authorizing resolution of the general meeting
Heidelberg, Germany, and Cambridge, UK, 20 April 2020 – The management board of 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) has decided today, based on the authorization of the general meeting of 19 December 2019 and with the approval of the supervisory board, to reduce the share capital of the Company by EUR 5,230,667.00 by way of redemption of 5,230,667 treasury shares (approx. 10 % of the share capital of the Company).
The redemption will come into effect at the time of the registration of the capital reduction with the commercial register. Each no-par value share will still represent an arithmetic proportion of the share capital of the Company of EUR 1.00. Upon such redemption the Company will not hold any treasury shares anymore.
*** end of ad hoc announcement ***
Tel. +49 6221 3540 125
|Waldhofer Str. 102|
|Phone:||+49 (0) 6221 3540 125|
|Fax:||+49 (0) 6221 3540 127|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1025247|
|End of Announcement||DGAP News Service|